| Name | IPN60090 |
| Description | IPN60090 is a novel, potent, orally bioavailable, renal-type glutaminase (GLS1)-specific inhibitor with an IC50 value of 31 nM for GLS1. IPN60090 has potential anticancer and immunostimulant/immunomodulatory activity, selectively targets, binds, and inhibits human glutaminase, and can be used to study GLS1-mediated diseases. |
| In vitro | IPN60090 has an IC50 against GLS1 and an EC50 against A549 cell proliferation of <100 nM.[1] |
| In vivo | IPN-60090 (100 mg/kg; oral administration; twice daily; 30 days;) causes tumor growth inhibition. IPN-60090 is robust in vivo target engagement in a dose-dependent manner. The glutamate/glutamine ratios and the free plasma concentrations of IPN-60090 at 4 hours post-dose on both day 4 and day 28 are all decreased.[2]
IPN60090 (3 mg/kg; i.v.; 10 mg/kg for p.o.) has excellent pharmacokinetic properties, with CL=4.1 mL/min/kg, t1/2=1 hour, Cmax=19 μM, F%=89%.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 27.5 mg/mL (51.64 mM), Sonication is recommended.
|
| Keywords | IPN-60090 | IPN60090 | IPN 60090 | Glutaminase GLS1 (KGA) | GLS1 |
| Inhibitors Related | N-Phenylacrylamide | MSNBA | LDN-212320 | Decanoic Acid | Brilliant Yellow | Evans blue | SLC26A3-IN-1 | BAY-876 | Cystamine dihydrochloride | Phloretin | Telaglenastat | 6-Diazo-5-oxo-L-nor-Leucine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
